Visual symptoms in Parkinson's disease and Parkinson's disease dementia
Visual symptoms are common in PD and PD dementia and include difficulty reading, double vision, illusions, feelings of presence and passage, and complex visual hallucinations. Despite the established prognostic implications of complex visual hallucinations, the interaction between cognitive decline,...
Saved in:
Published in | Movement disorders Vol. 26; no. 13; pp. 2387 - 2395 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.11.2011
Wiley |
Subjects | |
Online Access | Get full text |
ISSN | 0885-3185 1531-8257 1531-8257 |
DOI | 10.1002/mds.23891 |
Cover
Abstract | Visual symptoms are common in PD and PD dementia and include difficulty reading, double vision, illusions, feelings of presence and passage, and complex visual hallucinations. Despite the established prognostic implications of complex visual hallucinations, the interaction between cognitive decline, visual impairment, and other visual symptoms remains poorly understood. Our aim was to characterize the spectrum of visual symptomatology in PD and examine clinical predictors for their occurrence. Sixty‐four subjects with PD, 26 with PD dementia, and 32 age‐matched controls were assessed for visual symptoms, cognitive impairment, and ocular pathology. Complex visual hallucinations were common in PD (17%) and PD dementia (89%). Dementia subjects reported illusions (65%) and presence (62%) more frequently than PD or control subjects, but the frequency of passage hallucinations in PD and PD dementia groups was equivalent (48% versus 69%, respectively; P = 0.102). Visual acuity and contrast sensitivity was impaired in parkinsonian subjects, with disease severity and age emerging as the key predictors. Regression analysis identified a variety of factors independently predictive of complex visual hallucinations (e.g., dementia, visual acuity, and depression), illusions (e.g., excessive daytime somnolence and disease severity), and presence (e.g., rapid eye movement sleep behavior disorder and excessive daytime somnolence). Our results demonstrate that different “hallucinatory” experiences in PD do not necessarily share common disease predictors and may, therefore, be driven by different pathophysiological mechanisms. If confirmed, such a finding will have important implications for future studies of visual symptoms and cognitive decline in PD and PD dementia. © 2011 Movement Disorder Society |
---|---|
AbstractList | Visual symptoms are common in PD and PD dementia and include difficulty reading, double vision, illusions, feelings of presence and passage, and complex visual hallucinations. Despite the established prognostic implications of complex visual hallucinations, the interaction between cognitive decline, visual impairment, and other visual symptoms remains poorly understood. Our aim was to characterize the spectrum of visual symptomatology in PD and examine clinical predictors for their occurrence. Sixty‐four subjects with PD, 26 with PD dementia, and 32 age‐matched controls were assessed for visual symptoms, cognitive impairment, and ocular pathology. Complex visual hallucinations were common in PD (17%) and PD dementia (89%). Dementia subjects reported illusions (65%) and presence (62%) more frequently than PD or control subjects, but the frequency of passage hallucinations in PD and PD dementia groups was equivalent (48% versus 69%, respectively; P = 0.102). Visual acuity and contrast sensitivity was impaired in parkinsonian subjects, with disease severity and age emerging as the key predictors. Regression analysis identified a variety of factors independently predictive of complex visual hallucinations (e.g., dementia, visual acuity, and depression), illusions (e.g., excessive daytime somnolence and disease severity), and presence (e.g., rapid eye movement sleep behavior disorder and excessive daytime somnolence). Our results demonstrate that different “hallucinatory” experiences in PD do not necessarily share common disease predictors and may, therefore, be driven by different pathophysiological mechanisms. If confirmed, such a finding will have important implications for future studies of visual symptoms and cognitive decline in PD and PD dementia. © 2011 Movement Disorder Society Visual symptoms are common in PD and PD dementia and include difficulty reading, double vision, illusions, feelings of presence and passage, and complex visual hallucinations. Despite the established prognostic implications of complex visual hallucinations, the interaction between cognitive decline, visual impairment, and other visual symptoms remains poorly understood. Our aim was to characterize the spectrum of visual symptomatology in PD and examine clinical predictors for their occurrence. Sixty‐four subjects with PD, 26 with PD dementia, and 32 age‐matched controls were assessed for visual symptoms, cognitive impairment, and ocular pathology. Complex visual hallucinations were common in PD (17%) and PD dementia (89%). Dementia subjects reported illusions (65%) and presence (62%) more frequently than PD or control subjects, but the frequency of passage hallucinations in PD and PD dementia groups was equivalent (48% versus 69%, respectively; P = 0.102). Visual acuity and contrast sensitivity was impaired in parkinsonian subjects, with disease severity and age emerging as the key predictors. Regression analysis identified a variety of factors independently predictive of complex visual hallucinations (e.g., dementia, visual acuity, and depression), illusions (e.g., excessive daytime somnolence and disease severity), and presence (e.g., rapid eye movement sleep behavior disorder and excessive daytime somnolence). Our results demonstrate that different “hallucinatory” experiences in PD do not necessarily share common disease predictors and may, therefore, be driven by different pathophysiological mechanisms. If confirmed, such a finding will have important implications for future studies of visual symptoms and cognitive decline in PD and PD dementia. © 2011 Movement Disorder Society Visual symptoms are common in PD and PD dementia and include difficulty reading, double vision, illusions, feelings of presence and passage, and complex visual hallucinations. Despite the established prognostic implications of complex visual hallucinations, the interaction between cognitive decline, visual impairment, and other visual symptoms remains poorly understood. Our aim was to characterize the spectrum of visual symptomatology in PD and examine clinical predictors for their occurrence. Sixty-four subjects with PD, 26 with PD dementia, and 32 age-matched controls were assessed for visual symptoms, cognitive impairment, and ocular pathology. Complex visual hallucinations were common in PD (17%) and PD dementia (89%). Dementia subjects reported illusions (65%) and presence (62%) more frequently than PD or control subjects, but the frequency of passage hallucinations in PD and PD dementia groups was equivalent (48% versus 69%, respectively; P = 0.102). Visual acuity and contrast sensitivity was impaired in parkinsonian subjects, with disease severity and age emerging as the key predictors. Regression analysis identified a variety of factors independently predictive of complex visual hallucinations (e.g., dementia, visual acuity, and depression), illusions (e.g., excessive daytime somnolence and disease severity), and presence (e.g., rapid eye movement sleep behavior disorder and excessive daytime somnolence). Our results demonstrate that different "hallucinatory" experiences in PD do not necessarily share common disease predictors and may, therefore, be driven by different pathophysiological mechanisms. If confirmed, such a finding will have important implications for future studies of visual symptoms and cognitive decline in PD and PD dementia.Visual symptoms are common in PD and PD dementia and include difficulty reading, double vision, illusions, feelings of presence and passage, and complex visual hallucinations. Despite the established prognostic implications of complex visual hallucinations, the interaction between cognitive decline, visual impairment, and other visual symptoms remains poorly understood. Our aim was to characterize the spectrum of visual symptomatology in PD and examine clinical predictors for their occurrence. Sixty-four subjects with PD, 26 with PD dementia, and 32 age-matched controls were assessed for visual symptoms, cognitive impairment, and ocular pathology. Complex visual hallucinations were common in PD (17%) and PD dementia (89%). Dementia subjects reported illusions (65%) and presence (62%) more frequently than PD or control subjects, but the frequency of passage hallucinations in PD and PD dementia groups was equivalent (48% versus 69%, respectively; P = 0.102). Visual acuity and contrast sensitivity was impaired in parkinsonian subjects, with disease severity and age emerging as the key predictors. Regression analysis identified a variety of factors independently predictive of complex visual hallucinations (e.g., dementia, visual acuity, and depression), illusions (e.g., excessive daytime somnolence and disease severity), and presence (e.g., rapid eye movement sleep behavior disorder and excessive daytime somnolence). Our results demonstrate that different "hallucinatory" experiences in PD do not necessarily share common disease predictors and may, therefore, be driven by different pathophysiological mechanisms. If confirmed, such a finding will have important implications for future studies of visual symptoms and cognitive decline in PD and PD dementia. Visual symptoms are common in PD and PD dementia and include difficulty reading, double vision, illusions, feelings of presence and passage, and complex visual hallucinations. Despite the established prognostic implications of complex visual hallucinations, the interaction between cognitive decline, visual impairment, and other visual symptoms remains poorly understood. Our aim was to characterize the spectrum of visual symptomatology in PD and examine clinical predictors for their occurrence. Sixty-four subjects with PD, 26 with PD dementia, and 32 age-matched controls were assessed for visual symptoms, cognitive impairment, and ocular pathology. Complex visual hallucinations were common in PD (17%) and PD dementia (89%). Dementia subjects reported illusions (65%) and presence (62%) more frequently than PD or control subjects, but the frequency of passage hallucinations in PD and PD dementia groups was equivalent (48% versus 69%, respectively; P = 0.102). Visual acuity and contrast sensitivity was impaired in parkinsonian subjects, with disease severity and age emerging as the key predictors. Regression analysis identified a variety of factors independently predictive of complex visual hallucinations (e.g., dementia, visual acuity, and depression), illusions (e.g., excessive daytime somnolence and disease severity), and presence (e.g., rapid eye movement sleep behavior disorder and excessive daytime somnolence). Our results demonstrate that different "hallucinatory" experiences in PD do not necessarily share common disease predictors and may, therefore, be driven by different pathophysiological mechanisms. If confirmed, such a finding will have important implications for future studies of visual symptoms and cognitive decline in PD and PD dementia. |
Author | Burn, David J. Archibald, Neil K. Mosimann, Urs P. Clarke, Mike P. |
Author_xml | – sequence: 1 givenname: Neil K. surname: Archibald fullname: Archibald, Neil K. email: neilarchie@mac.com organization: Institute for Aging and Health, Newcastle University, Newcastle upon Tyne, United Kingdom – sequence: 2 givenname: Mike P. surname: Clarke fullname: Clarke, Mike P. organization: Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom – sequence: 3 givenname: Urs P. surname: Mosimann fullname: Mosimann, Urs P. organization: Institute for Aging and Health, Newcastle University, Newcastle upon Tyne, United Kingdom – sequence: 4 givenname: David J. surname: Burn fullname: Burn, David J. organization: Institute for Aging and Health, Newcastle University, Newcastle upon Tyne, United Kingdom |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25262489$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21953737$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kU1v1DAQhi3Uim4LB_4AygVVHNL6I2M7R7TQBWlbvgpIXKxJ7EiGxNlmsqL77xvYXSqhchpp9DyvZvQes4PUp8DYM8HPBOfyvPN0JpUtxSM2E6BEbiWYAzbj1kKuhIUjdkz0g3MhQOjH7EiKEpRRZsYWXyOtsc1o063GvqMspuwDDj9joj6dUuYjBaSQYfIP7n3oQhojPmGHDbYUnu7mCfty8eZ6_jZfvl-8m79a5nUBVuSmBl5BI4rCatMEhAqQQ11okFgV6LU0Xk-nBYVGi6bxWpVYCBQGDPcVqBN2us1dDf3NOtDoukh1aFtMoV-TKzmUWkluJ_L5jlxXXfBuNcQOh43b_z4BL3YAUo1tM2CqI91zILUsbDlx51uuHnqiITSujiOOsU_jgLF1grvfLbipBfenhcl4-Y-xD32I3aX_im3Y_B90l68_7418a0Qaw-1fYyrH6ekvcN-uFu7i4_f5tfmk3VLdAfn2pCY |
CitedBy_id | crossref_primary_10_3233_JPD_213143 crossref_primary_10_1007_s00717_022_00516_x crossref_primary_10_1016_j_ajpath_2024_01_017 crossref_primary_10_1017_cjn_2017_39 crossref_primary_10_1007_s00415_020_09925_x crossref_primary_10_1186_s12916_018_1016_8 crossref_primary_10_2217_nmt_2016_0009 crossref_primary_10_3389_fnagi_2022_818597 crossref_primary_10_1024_1016_264X_a000399 crossref_primary_10_3758_s13423_016_1168_5 crossref_primary_10_1159_000514175 crossref_primary_10_1152_jn_00681_2017 crossref_primary_10_1007_s00415_022_11014_0 crossref_primary_10_4103_jcor_jcor_111_23 crossref_primary_10_1038_s41598_022_21847_4 crossref_primary_10_3233_JPD_191830 crossref_primary_10_1016_j_jocn_2017_02_033 crossref_primary_10_3233_JPD_150686 crossref_primary_10_1016_j_neubiorev_2016_01_002 crossref_primary_10_1002_mdc3_12821 crossref_primary_10_1002_mds_26533 crossref_primary_10_1016_j_jagp_2014_12_190 crossref_primary_10_1007_s00401_018_01956_z crossref_primary_10_1016_j_visres_2015_08_011 crossref_primary_10_1176_appi_neurospych_17030063 crossref_primary_10_1212_WNL_0000000000006157 crossref_primary_10_1167_iovs_17_23230 crossref_primary_10_1016_j_parkreldis_2016_10_006 crossref_primary_10_1038_s41598_022_22037_y crossref_primary_10_3389_fnins_2021_718820 crossref_primary_10_1016_j_jagp_2015_10_007 crossref_primary_10_1371_journal_pone_0275738 crossref_primary_10_1186_s40478_018_0596_z crossref_primary_10_3389_fnins_2021_726476 crossref_primary_10_3389_fneur_2017_00206 crossref_primary_10_3389_fnins_2023_1205439 crossref_primary_10_1002_mds_27454 crossref_primary_10_1038_nrn_2017_62 crossref_primary_10_3238_PersNeuro_2016_09_16_01 crossref_primary_10_3390_diagnostics11122380 crossref_primary_10_1002_mds_28182 crossref_primary_10_1080_09286586_2024_2343725 crossref_primary_10_3390_neurolint15010012 crossref_primary_10_1109_RBME_2022_3161352 crossref_primary_10_1007_s10792_018_0934_y crossref_primary_10_1016_j_psiq_2021_100347 crossref_primary_10_1038_eye_2012_205 crossref_primary_10_3390_vision2010002 crossref_primary_10_1093_texcom_tgab042 crossref_primary_10_1097_WNO_0000000000002235 crossref_primary_10_1007_s00415_020_10304_9 crossref_primary_10_3389_fnins_2020_567129 crossref_primary_10_1007_s00115_021_01165_2 crossref_primary_10_1007_s00415_018_9051_0 crossref_primary_10_1016_j_mehy_2020_110326 crossref_primary_10_1134_S0362119717080072 crossref_primary_10_1021_acschemneuro_8b00383 crossref_primary_10_31083_j_jin2301023 crossref_primary_10_1016_j_baga_2013_05_002 crossref_primary_10_1016_j_parkreldis_2018_05_023 crossref_primary_10_17116_jnevro2018118062105 crossref_primary_10_3390_jpm14030270 crossref_primary_10_3389_fnins_2021_799526 crossref_primary_10_1007_s00115_013_3754_3 crossref_primary_10_3390_proteomes10010004 crossref_primary_10_1136_jnnp_2016_314832 crossref_primary_10_1016_j_neulet_2014_04_027 crossref_primary_10_1016_j_bbr_2018_03_003 crossref_primary_10_1080_08820538_2021_1987482 crossref_primary_10_1016_j_arr_2023_101954 crossref_primary_10_1136_jnnp_2022_329342 crossref_primary_10_1016_j_parkreldis_2022_06_006 crossref_primary_10_3389_fneur_2020_533375 crossref_primary_10_1093_schbul_sbv073 crossref_primary_10_3233_JPD_223238 crossref_primary_10_3390_ijms24076363 crossref_primary_10_1002_cne_25481 crossref_primary_10_5498_wjp_v11_i8_491 crossref_primary_10_1016_j_gaitpost_2016_04_024 crossref_primary_10_1016_j_parkreldis_2024_107037 crossref_primary_10_1002_mds_27392 crossref_primary_10_1186_s12883_019_1365_8 crossref_primary_10_3233_JPD_202324 crossref_primary_10_3233_JAD_201516 crossref_primary_10_3390_biom14010073 crossref_primary_10_1038_nrneurol_2016_200 crossref_primary_10_1016_j_neucli_2021_03_005 crossref_primary_10_1016_j_parkreldis_2012_07_012 crossref_primary_10_1080_13546805_2021_1960812 crossref_primary_10_1212_WNL_0000000000006007 crossref_primary_10_1155_2020_2410863 crossref_primary_10_1016_j_parkreldis_2017_09_024 crossref_primary_10_1111_opo_12220 crossref_primary_10_1111_ane_13380 crossref_primary_10_1007_s00702_019_02097_7 crossref_primary_10_1002_gps_5950 crossref_primary_10_1177_08919887231195220 crossref_primary_10_1007_s11940_018_0519_0 crossref_primary_10_1186_1471_2458_14_815 crossref_primary_10_1111_psyg_12771 crossref_primary_10_1038_s41598_020_77833_1 crossref_primary_10_1093_brain_aww175 crossref_primary_10_3389_fnagi_2022_783634 crossref_primary_10_1080_01658107_2017_1305422 crossref_primary_10_1111_j_1755_3768_2012_02544_x crossref_primary_10_1016_j_parkreldis_2012_05_016 crossref_primary_10_12659_MSM_890861 crossref_primary_10_1002_mdc3_12479 crossref_primary_10_1055_a_1210_7737 crossref_primary_10_1016_j_parkreldis_2017_09_015 crossref_primary_10_1016_j_neuropsychologia_2014_01_017 crossref_primary_10_1016_j_parkreldis_2017_02_014 crossref_primary_10_1212_WNL_0000000000009214 crossref_primary_10_1007_s40265_016_0600_5 crossref_primary_10_1097_HRP_0000000000000068 crossref_primary_10_3233_JPD_181523 crossref_primary_10_1038_nrneurol_2014_79 crossref_primary_10_1016_j_neuroscience_2013_09_013 crossref_primary_10_1155_2021_2704755 crossref_primary_10_1016_j_neubiorev_2023_105081 crossref_primary_10_1155_2020_3107185 crossref_primary_10_3389_fneur_2023_1158188 crossref_primary_10_1051_bioconf_20248601028 crossref_primary_10_1016_j_parkreldis_2015_08_031 crossref_primary_10_4103_0028_3886_349658 crossref_primary_10_1038_srep36284 crossref_primary_10_3233_JPD_202103 crossref_primary_10_1007_s40800_018_0082_3 crossref_primary_10_3109_02713683_2014_930154 crossref_primary_10_1097_WCO_0000000000000882 crossref_primary_10_1186_s40478_016_0334_3 crossref_primary_10_3233_JAD_180834 crossref_primary_10_1038_s41537_022_00237_9 crossref_primary_10_1080_08164622_2021_1984179 crossref_primary_10_3389_fnins_2019_00080 crossref_primary_10_1002_mds_25389 crossref_primary_10_1002_mds_25543 crossref_primary_10_1093_ageing_afaa043 crossref_primary_10_1007_s00415_019_09430_w crossref_primary_10_1007_s00415_020_10094_0 crossref_primary_10_1055_a_2339_7375 crossref_primary_10_1093_brain_awac094 crossref_primary_10_7759_cureus_55436 crossref_primary_10_17116_jnevro201711791124_131 crossref_primary_10_1016_j_parkreldis_2013_12_009 crossref_primary_10_1024_1016_264X_a000402 crossref_primary_10_1002_mds_27557 crossref_primary_10_3390_ijms24054391 crossref_primary_10_1002_mdc3_12453 crossref_primary_10_1016_j_neurol_2019_11_002 crossref_primary_10_1016_j_parkreldis_2015_03_020 |
Cites_doi | 10.1002/mds.20308 10.1093/brain/121.10.1819 10.1016/j.jns.2009.08.014 10.1007/s00415-0060-0254-4 10.1002/mds.21956 10.1017/S0140525X05000130 10.1093/brain/awp223 10.1002/mds.20582 10.1001/archneur.61.1.97 10.1002/mds.22829 10.1111/j.1600-0404.2007.00818.x 10.1177/089198879901200403 10.3928/0191-3913-19960501-04 10.1016/S0140-6736(96)90869-7 10.1212/01.WNL.0000103444.45882.D8 10.1002/gps.1965 10.1136/jnnp.55.3.181 10.1016/j.visres.2004.11.006 10.1016/0022-3956(75)90026-6 10.1001/archneurol.2009.221 10.1176/jnp.12.2.233 10.1002/mds.20844 10.1212/01.WNL.0000141853.27081.BD 10.1007/PL00007730 10.1192/bjp.169.4.459 10.1016/j.parkreldis.2010.01.003 10.1212/WNL.42.4.887 10.1001/archneur.1996.00550120077019 10.1177/0891988705284739 10.1002/mds.23429 10.1002/mds.10429 10.1093/brain/110.6.1675 10.1212/01.wnl.0000191565.11065.11 10.1001/archopht.119.7.1050 10.1002/mds.21507 10.1136/jnnp.63.4.434 10.1016/S0165-1781(00)00227-4 10.1002/mds.23411 10.1093/brain/123.4.733 10.1093/ageing/25.2.113 10.1016/S1353-8020(99)00062-0 10.1136/jnnp.51.11.1401 10.1212/WNL.0b013e3181fd6158 |
ContentType | Journal Article |
Copyright | Copyright © 2011 Movement Disorder Society 2015 INIST-CNRS Copyright © 2011 Movement Disorder Society. |
Copyright_xml | – notice: Copyright © 2011 Movement Disorder Society – notice: 2015 INIST-CNRS – notice: Copyright © 2011 Movement Disorder Society. |
DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1002/mds.23891 |
DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1531-8257 |
EndPage | 2395 |
ExternalDocumentID | 21953737 25262489 10_1002_mds_23891 MDS23891 ark_67375_WNG_FQZCT7R6_L |
Genre | article Research Support, Non-U.S. Gov't Journal Article Comparative Study |
GrantInformation_xml | – fundername: Parkinson's UK grantid: F-0701 |
GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 123 1CY 1L6 1OB 1OC 1ZS 31~ 33P 3PY 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANHP AANLZ AAONW AASGY AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEFGJ AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFFPM AFGKR AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AHMBA AIACR AIDQK AIDYY AIQQE AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE FUBAC FYBCS G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M6M MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RX1 RYL SAMSI SUPJJ SV3 TEORI TWZ UB1 V2E V9Y W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WVDHM WXI WXSBR XG1 XV2 ZGI ZZTAW ~IA ~WT AAHHS AAYXX ACCFJ AEEZP AEQDE AIWBW AJBDE CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c4581-7c50b5f144867fea5b5a05c4652ab4ad627d6537e3a761ffd639a41a17570db53 |
IEDL.DBID | DR2 |
ISSN | 0885-3185 1531-8257 |
IngestDate | Thu Jul 10 18:11:52 EDT 2025 Mon Jul 21 06:03:07 EDT 2025 Mon Jul 21 09:17:24 EDT 2025 Tue Jul 01 01:44:12 EDT 2025 Thu Apr 24 22:56:09 EDT 2025 Sun Sep 21 06:20:21 EDT 2025 Sun Sep 21 06:20:05 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 13 |
Keywords | Nervous system diseases complex visual hallucinations Parkinson's disease Parkinson's disease dementia Parkinson disease Visual acuity Visual hallucination contrast sensitivity Cerebral disorder Sensitivity Central nervous system disease Degenerative disease Extrapyramidal syndrome Dementia |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor CC BY 4.0 Copyright © 2011 Movement Disorder Society. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4581-7c50b5f144867fea5b5a05c4652ab4ad627d6537e3a761ffd639a41a17570db53 |
Notes | Full financial disclosures and author roles may be found in the online version of this article. Relevant conflicts of interest/financial disclosures: Nothing to report. ArticleID:MDS23891 Funding agencies: N.K.A. was funded by Parkinson's UK for this work. We acknowledge support from the UK NIHR Biomedical Research Center for Aging and Age-Related Disease award to the Newcastle upon Tyne Hospitals NHS Foundation Trust. istex:148FC0A3A8EAF6B5B722AA70A0BC42F1F5597F08 ark:/67375/WNG-FQZCT7R6-L Nothing to report. Relevant conflicts of interest/financial disclosures Funding agencies N.K.A. was funded by Parkinson's UK for this work. We acknowledge support from the UK NIHR Biomedical Research Center for Aging and Age‐Related Disease award to the Newcastle upon Tyne Hospitals NHS Foundation Trust. ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
PMID | 21953737 |
PQID | 905963208 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_905963208 pubmed_primary_21953737 pascalfrancis_primary_25262489 crossref_citationtrail_10_1002_mds_23891 crossref_primary_10_1002_mds_23891 wiley_primary_10_1002_mds_23891_MDS23891 istex_primary_ark_67375_WNG_FQZCT7R6_L |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | November 2011 |
PublicationDateYYYYMMDD | 2011-11-01 |
PublicationDate_xml | – month: 11 year: 2011 text: November 2011 |
PublicationDecade | 2010 |
PublicationPlace | Hoboken |
PublicationPlace_xml | – name: Hoboken – name: Hoboken, NJ – name: United States |
PublicationTitle | Movement disorders |
PublicationTitleAlternate | Mov. Disord |
PublicationYear | 2011 |
Publisher | Wiley Subscription Services, Inc., A Wiley Company Wiley |
Publisher_xml | – name: Wiley Subscription Services, Inc., A Wiley Company – name: Wiley |
References | Newman EJ, Breen K, Patterson J, Hadley DM, Grosset KA, Grosset DG. Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland. Mov Disord 2009; 24: 2379-2385. Bucks RS, Ashworth DL, Wilcock GK, Siegfried K. Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age Ageing 1996; 25: 113-120. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol 1996; 53: 1265-1268. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22: 1689-707; quiz, 1837. Razmy A, Lang AE, Shapiro CM. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol 2004; 61: 97-102. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837-844. Meppelink AM, de Jong BM, Renken R, Leenders KL, Cornelissen FW, Van Laar T. Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations. Brain 2009; 132: 2980-2993. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198. Collerton D, Perry E, McKeith I. Why people see things that are not there: a novel perception and attention deficit model for recurrent complex visual hallucinations. Behav Brain Sci 2005; 28: 737-757; discussion 757-794. Diederich NJ, Goetz CG, Raman R, Pappert EJ, Leurgans S, Piery V. Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol 1998; 21: 289-295. Brown GG, Rahill AA, Gorell JM, et al. Validity of the Dementia Rating Scale in assessing cognitive function in Parkinson's disease. J Geriatr Psychiatry Neurol 1999; 12: 180-188. Castelo-Branco M, Mendes M, Silva F, et al. Motion integration deficits are independent of magnocelluar impairment in Parkinson's disease. Neuropsychologia 2008. doi: 10.1016/j.neuropsychologia.2008.09.003. Koerts J, Borg M, Meppelink AM, Leenders KL, Beilen M, van Laar T. Attentional and perceptual impairments in Parkinson's disease with visual hallucinations. Parkinsonism Relat Disord 2010; 16: 270-274. Price MJ, Feldman RG, Adelberg D, Kayne H. Abnormalities in color vision and contrast sensitivity in Parkinson's disease. Neurology 1992; 42: 887-890. Brodsky MA, Godbold J, Roth T, Olanow CW. Sleepiness in Parkinson's disease: a controlled study. Mov Disord 2003; 18: 668-672. Biousse V, Skibell BC, Watts RL, Loupe DN, Drews-Botsch C, Newman NJ. Ophthalmologic features of Parkinson's disease.[see comment]. Neurology 2004; 62: 177-180. Lo RY, Tanner CM, Albers KB, et al. Clinical features in early Parkinson disease and survival. Arch Neurol 2009; 66: 1353-1358. Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006; 21: 916-923. Benke T. Peduncular hallucinosis: a syndrome of impaired reality monitoring. J Neurol 2006; 253: 1561-1571. Davidsdottir S, Cronin-Golomb A, Lee A. Visual and spatial symptoms in Parkinson's disease. Vision Res 2005; 45: 1285-1296. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2001; 119: 1050-1058. Ohayon MM. Prevalence of hallucinations and their pathological associations in the general population. Psychiatry Res 2000; 97: 153-164. Graham JM, Grunewald RA, Sagar HJ. Hallucinosis in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 63: 434-440. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology, and risk factors. Brain 2000; 123: 733-745. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010; 25: 2649-2653. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184. Levin BE, Llabre MM, Weiner WJ. Parkinson's disease and depression: psychometric properties of the Beck Depression Inventory. J Neurol Neurosurg Psychiatry 1988; 51: 1401-1404. Goetz CG, Ouyang B, Negron A, Stebbins GT. Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study. Neurology 2010; 75: 1773-1779. Fenelon G, Alves G. Epidemiology of psychosis in Parkinson's disease. J Neurol Sci 2010; 289: 12-17. Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 2000; 12: 233-239. Repka MX, Claro MC, Loupe DN, Reich SG. Ocular motility in Parkinson's disease. J Pediatr Ophthalmol Strabismus 1996; 33: 144-147. Onofrj M, Thomas A, D'Andreamatteo G, et al. Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up. Neurolog Sci 2002; 23( Suppl 2): S91-S94. Stebbins GT, Goetz CG, Carrillo MC, et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology 2004; 63: 1409-1416. Uc EY, Rizzo M, Anderson SW, Qian S, Rodnitzky RL, Dawson JD. Visual dysfunction in Parkinson disease without dementia. Neurology 2005; 65: 1907-1913. Pacchetti C, Manni R, Zangaglia R, et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease. Mov Disord 2005; 20: 1439-1448. Teunisse RJ, Cruysberg JR, Hoefnagels WH, Verbeek AL, Zitman FG. Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome [see comment]. Lancet 1996; 347: 794-797. Ohayon MM, Priest RG, Caulet M, Guilleminault C. Hypnagogic and hypnopompic hallucinations: pathological phenomena? Br J Psychiatry 1996; 169: 459-467. Fenelon G, Soulas T, Cleret de Langavant L, Trinkler I, Bachoud-Lévi C. Feeling of a presence in PD. J Neurol Neurosurg Psychiatry (in press). Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord 2005; 20: 130-140. Matsui H, Udaka F, Tamura A, et al. Impaired visual acuity as a risk factor for visual hallucinations in Parkinson's disease. J Ger Psychiatry Neurol 2006; 19: 36-40. Manford M, Andermann F. Complex visual hallucinations. Clinical and neurobiological insights. Brain 1998; 121: 1819-1840. Bodis-Wollner I, Marx M, Mitra S, Bobak P, Mylin L, Yahr M. Visual dysfunction in Parkinson's disease. Brain 1987; 110: 1675-1698. Giladi N, Shabtai H, Simon ES, Biran S, Tal J, Korczyn AD. Construction of freezing of gait questionnaire for patients with Parkinsonism. Parkinsonism Relat Disord 2000; 6: 165-170. Mosimann UP, Collerton D, Dudley R, et al. A semi-structured interview to assess visual hallucinations in older people. Int J Geriatr Psychiatry 2008; 23: 712-718. Boeve BF, Silber MH, Ferman TJ, Smith GE, Petersen RC. Validation of a questionnaire for the diagnosis of REM sleep behavior disorder. Neurology 2002; 58: A509. Llebaria G, Pagonabarraga J, Martinez-Corral M, et al. Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease. Mov Disord 2010; 25: 2785-2791. Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation, and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol 1998; 245( Suppl 1): S10-S14. 2009; 66 2002; 58 2004; 63 2010; 75 2009; 24 2004; 61 2010; 16 2004; 62 2000; 6 1997; 63 2010; 289 2009; 132 2008 1975; 12 2006; 253 2005; 20 2006; 19 2005; 65 1988; 51 2003; 18 1996; 169 1998; 21 1992; 55 2005; 28 2005; 45 1996; 53 1996; 33 1996; 347 2010; 25 1987; 110 2006; 21 2000; 12 2002; 23 2000; 97 1987 1999; 12 2008; 23 2000; 123 1992; 42 1996; 25 2001; 119 1998; 121 2007; 22 1998; 245 Onofrj M (e_1_2_6_41_2) 2002; 23 Fenelon G (e_1_2_6_10_2) e_1_2_6_31_2 e_1_2_6_30_2 e_1_2_6_18_2 e_1_2_6_19_2 e_1_2_6_12_2 e_1_2_6_35_2 e_1_2_6_13_2 e_1_2_6_33_2 e_1_2_6_11_2 Castelo‐Branco M (e_1_2_6_15_2) 2008 e_1_2_6_32_2 e_1_2_6_39_2 e_1_2_6_17_2 e_1_2_6_38_2 e_1_2_6_14_2 e_1_2_6_37_2 e_1_2_6_36_2 e_1_2_6_42_2 e_1_2_6_20_2 Diederich NJ (e_1_2_6_16_2) 1998; 21 e_1_2_6_40_2 Boeve BF (e_1_2_6_25_2) 2002; 58 Repka MX (e_1_2_6_34_2) 1996; 33 e_1_2_6_8_2 e_1_2_6_7_2 e_1_2_6_9_2 e_1_2_6_29_2 e_1_2_6_4_2 e_1_2_6_3_2 e_1_2_6_6_2 e_1_2_6_5_2 e_1_2_6_24_2 e_1_2_6_47_2 e_1_2_6_23_2 e_1_2_6_48_2 e_1_2_6_2_2 e_1_2_6_22_2 e_1_2_6_49_2 e_1_2_6_21_2 e_1_2_6_28_2 e_1_2_6_43_2 e_1_2_6_27_2 e_1_2_6_44_2 e_1_2_6_26_2 e_1_2_6_45_2 e_1_2_6_46_2 |
References_xml | – reference: Repka MX, Claro MC, Loupe DN, Reich SG. Ocular motility in Parkinson's disease. J Pediatr Ophthalmol Strabismus 1996; 33: 144-147. – reference: Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198. – reference: Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology, and risk factors. Brain 2000; 123: 733-745. – reference: Manford M, Andermann F. Complex visual hallucinations. Clinical and neurobiological insights. Brain 1998; 121: 1819-1840. – reference: Diederich NJ, Goetz CG, Raman R, Pappert EJ, Leurgans S, Piery V. Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol 1998; 21: 289-295. – reference: Onofrj M, Thomas A, D'Andreamatteo G, et al. Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up. Neurolog Sci 2002; 23( Suppl 2): S91-S94. – reference: Koerts J, Borg M, Meppelink AM, Leenders KL, Beilen M, van Laar T. Attentional and perceptual impairments in Parkinson's disease with visual hallucinations. Parkinsonism Relat Disord 2010; 16: 270-274. – reference: Giladi N, Shabtai H, Simon ES, Biran S, Tal J, Korczyn AD. Construction of freezing of gait questionnaire for patients with Parkinsonism. Parkinsonism Relat Disord 2000; 6: 165-170. – reference: Ohayon MM, Priest RG, Caulet M, Guilleminault C. Hypnagogic and hypnopompic hallucinations: pathological phenomena? Br J Psychiatry 1996; 169: 459-467. – reference: Goetz CG, Ouyang B, Negron A, Stebbins GT. Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study. Neurology 2010; 75: 1773-1779. – reference: Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord 2005; 20: 130-140. – reference: Castelo-Branco M, Mendes M, Silva F, et al. Motion integration deficits are independent of magnocelluar impairment in Parkinson's disease. Neuropsychologia 2008. doi: 10.1016/j.neuropsychologia.2008.09.003. – reference: Matsui H, Udaka F, Tamura A, et al. Impaired visual acuity as a risk factor for visual hallucinations in Parkinson's disease. J Ger Psychiatry Neurol 2006; 19: 36-40. – reference: Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010; 25: 2649-2653. – reference: Benke T. Peduncular hallucinosis: a syndrome of impaired reality monitoring. J Neurol 2006; 253: 1561-1571. – reference: Brown GG, Rahill AA, Gorell JM, et al. Validity of the Dementia Rating Scale in assessing cognitive function in Parkinson's disease. J Geriatr Psychiatry Neurol 1999; 12: 180-188. – reference: Graham JM, Grunewald RA, Sagar HJ. Hallucinosis in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 63: 434-440. – reference: Fenelon G, Alves G. Epidemiology of psychosis in Parkinson's disease. J Neurol Sci 2010; 289: 12-17. – reference: Boeve BF, Silber MH, Ferman TJ, Smith GE, Petersen RC. Validation of a questionnaire for the diagnosis of REM sleep behavior disorder. Neurology 2002; 58: A509. – reference: Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837-844. – reference: Mosimann UP, Collerton D, Dudley R, et al. A semi-structured interview to assess visual hallucinations in older people. Int J Geriatr Psychiatry 2008; 23: 712-718. – reference: Llebaria G, Pagonabarraga J, Martinez-Corral M, et al. Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease. Mov Disord 2010; 25: 2785-2791. – reference: Bodis-Wollner I, Marx M, Mitra S, Bobak P, Mylin L, Yahr M. Visual dysfunction in Parkinson's disease. Brain 1987; 110: 1675-1698. – reference: Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184. – reference: Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation, and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol 1998; 245( Suppl 1): S10-S14. – reference: Davidsdottir S, Cronin-Golomb A, Lee A. Visual and spatial symptoms in Parkinson's disease. Vision Res 2005; 45: 1285-1296. – reference: Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006; 21: 916-923. – reference: Ohayon MM. Prevalence of hallucinations and their pathological associations in the general population. Psychiatry Res 2000; 97: 153-164. – reference: Brodsky MA, Godbold J, Roth T, Olanow CW. Sleepiness in Parkinson's disease: a controlled study. Mov Disord 2003; 18: 668-672. – reference: Lo RY, Tanner CM, Albers KB, et al. Clinical features in early Parkinson disease and survival. Arch Neurol 2009; 66: 1353-1358. – reference: Meppelink AM, de Jong BM, Renken R, Leenders KL, Cornelissen FW, Van Laar T. Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations. Brain 2009; 132: 2980-2993. – reference: Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 2000; 12: 233-239. – reference: Price MJ, Feldman RG, Adelberg D, Kayne H. Abnormalities in color vision and contrast sensitivity in Parkinson's disease. Neurology 1992; 42: 887-890. – reference: Stebbins GT, Goetz CG, Carrillo MC, et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology 2004; 63: 1409-1416. – reference: Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22: 1689-707; quiz, 1837. – reference: Bucks RS, Ashworth DL, Wilcock GK, Siegfried K. Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age Ageing 1996; 25: 113-120. – reference: Teunisse RJ, Cruysberg JR, Hoefnagels WH, Verbeek AL, Zitman FG. Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome [see comment]. Lancet 1996; 347: 794-797. – reference: Biousse V, Skibell BC, Watts RL, Loupe DN, Drews-Botsch C, Newman NJ. Ophthalmologic features of Parkinson's disease.[see comment]. Neurology 2004; 62: 177-180. – reference: Levin BE, Llabre MM, Weiner WJ. Parkinson's disease and depression: psychometric properties of the Beck Depression Inventory. J Neurol Neurosurg Psychiatry 1988; 51: 1401-1404. – reference: Razmy A, Lang AE, Shapiro CM. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol 2004; 61: 97-102. – reference: Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2001; 119: 1050-1058. – reference: Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol 1996; 53: 1265-1268. – reference: Newman EJ, Breen K, Patterson J, Hadley DM, Grosset KA, Grosset DG. Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland. Mov Disord 2009; 24: 2379-2385. – reference: Fenelon G, Soulas T, Cleret de Langavant L, Trinkler I, Bachoud-Lévi C. Feeling of a presence in PD. J Neurol Neurosurg Psychiatry (in press). – reference: Uc EY, Rizzo M, Anderson SW, Qian S, Rodnitzky RL, Dawson JD. Visual dysfunction in Parkinson disease without dementia. Neurology 2005; 65: 1907-1913. – reference: Collerton D, Perry E, McKeith I. Why people see things that are not there: a novel perception and attention deficit model for recurrent complex visual hallucinations. Behav Brain Sci 2005; 28: 737-757; discussion 757-794. – reference: Pacchetti C, Manni R, Zangaglia R, et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease. Mov Disord 2005; 20: 1439-1448. – volume: 169 start-page: 459 year: 1996 end-page: 467 article-title: Hypnagogic and hypnopompic hallucinations: pathological phenomena? publication-title: Br J Psychiatry – volume: 51 start-page: 1401 year: 1988 end-page: 1404 article-title: Parkinson's disease and depression: psychometric properties of the Beck Depression Inventory publication-title: J Neurol Neurosurg Psychiatry – volume: 23 start-page: 712 year: 2008 end-page: 718 article-title: A semi‐structured interview to assess visual hallucinations in older people publication-title: Int J Geriatr Psychiatry – volume: 75 start-page: 1773 year: 2010 end-page: 1779 article-title: Hallucinations and sleep disorders in PD: ten‐year prospective longitudinal study publication-title: Neurology – volume: 123 start-page: 733 year: 2000 end-page: 745 article-title: Hallucinations in Parkinson's disease: prevalence, phenomenology, and risk factors publication-title: Brain – volume: 63 start-page: 434 year: 1997 end-page: 440 article-title: Hallucinosis in idiopathic Parkinson's disease publication-title: J Neurol Neurosurg Psychiatry – volume: 97 start-page: 153 year: 2000 end-page: 164 article-title: Prevalence of hallucinations and their pathological associations in the general population publication-title: Psychiatry Res – volume: 12 start-page: 180 year: 1999 end-page: 188 article-title: Validity of the Dementia Rating Scale in assessing cognitive function in Parkinson's disease publication-title: J Geriatr Psychiatry Neurol – volume: 21 start-page: 916 year: 2006 end-page: 923 article-title: International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study publication-title: Mov Disord – volume: 42 start-page: 887 year: 1992 end-page: 890 article-title: Abnormalities in color vision and contrast sensitivity in Parkinson's disease publication-title: Neurology – year: 2008 article-title: Motion integration deficits are independent of magnocelluar impairment in Parkinson's disease publication-title: Neuropsychologia – volume: 6 start-page: 165 year: 2000 end-page: 170 article-title: Construction of freezing of gait questionnaire for patients with Parkinsonism publication-title: Parkinsonism Relat Disord – volume: 347 start-page: 794 year: 1996 end-page: 797 article-title: Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome [see comment] publication-title: Lancet – volume: 45 start-page: 1285 year: 2005 end-page: 1296 article-title: Visual and spatial symptoms in Parkinson's disease publication-title: Vision Res – volume: 19 start-page: 36 year: 2006 end-page: 40 article-title: Impaired visual acuity as a risk factor for visual hallucinations in Parkinson's disease publication-title: J Ger Psychiatry Neurol – volume: 20 start-page: 130 year: 2005 end-page: 140 article-title: Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model publication-title: Mov Disord – volume: 63 start-page: 1409 year: 2004 end-page: 1416 article-title: Altered cortical visual processing in PD with hallucinations: an fMRI study publication-title: Neurology – volume: 62 start-page: 177 year: 2004 end-page: 180 article-title: Ophthalmologic features of Parkinson's disease.[see comment] publication-title: Neurology – start-page: 153 year: 1987 end-page: 163 – volume: 23 issue: Suppl 2 year: 2002 end-page: S94 article-title: Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8‐year follow‐up publication-title: Neurolog Sci – volume: 28 start-page: 737 year: 2005 end-page: 757 article-title: Why people see things that are not there: a novel perception and attention deficit model for recurrent complex visual hallucinations publication-title: Behav Brain Sci – volume: 110 start-page: 1675 year: 1987 end-page: 1698 article-title: Visual dysfunction in Parkinson's disease publication-title: Brain – volume: 12 start-page: 233 year: 2000 end-page: 239 article-title: Validation of the NPI‐Q, a brief clinical form of the Neuropsychiatric Inventory publication-title: J Neuropsychiatry Clin Neurosci – volume: 25 start-page: 2785 year: 2010 end-page: 2791 article-title: Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease publication-title: Mov Disord – volume: 55 start-page: 181 year: 1992 end-page: 184 article-title: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico‐pathological study of 100 cases publication-title: J Neurol Neurosurg Psychiatry – volume: 12 start-page: 189 year: 1975 end-page: 198 article-title: “Mini‐mental state.” A practical method for grading the cognitive state of patients for the clinician publication-title: J Psychiatr Res – volume: 23 start-page: 837 year: 2008 end-page: 844 article-title: The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years publication-title: Mov Disord – volume: 132 start-page: 2980 year: 2009 end-page: 2993 article-title: Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations publication-title: Brain – volume: 21 start-page: 289 year: 1998 end-page: 295 article-title: Poor visual discrimination and visual hallucinations in Parkinson's disease publication-title: Clin Neuropharmacol – volume: 66 start-page: 1353 year: 2009 end-page: 1358 article-title: Clinical features in early Parkinson disease and survival publication-title: Arch Neurol – volume: 58 start-page: A509 year: 2002 article-title: Validation of a questionnaire for the diagnosis of REM sleep behavior disorder publication-title: Neurology – volume: 53 start-page: 1265 year: 1996 end-page: 1268 article-title: Visual hallucinations associated with Parkinson disease publication-title: Arch Neurol – volume: 16 start-page: 270 year: 2010 end-page: 274 article-title: Attentional and perceptual impairments in Parkinson's disease with visual hallucinations publication-title: Parkinsonism Relat Disord – volume: 24 start-page: 2379 year: 2009 end-page: 2385 article-title: Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland publication-title: Mov Disord – volume: 245 start-page: S10 issue: Suppl 1 year: 1998 end-page: S14 article-title: PDQ‐39: a review of the development, validation, and application of a Parkinson's disease quality of life questionnaire and its associated measures publication-title: J Neurol – volume: 253 start-page: 1561 year: 2006 end-page: 1571 article-title: Peduncular hallucinosis: a syndrome of impaired reality monitoring publication-title: J Neurol – volume: 20 start-page: 1439 year: 2005 end-page: 1448 article-title: Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease publication-title: Mov Disord – volume: 33 start-page: 144 year: 1996 end-page: 147 article-title: Ocular motility in Parkinson's disease publication-title: J Pediatr Ophthalmol Strabismus – volume: 61 start-page: 97 year: 2004 end-page: 102 article-title: Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists publication-title: Arch Neurol – volume: 119 start-page: 1050 year: 2001 end-page: 1058 article-title: Development of the 25‐item National Eye Institute Visual Function Questionnaire publication-title: Arch Ophthalmol – volume: 25 start-page: 113 year: 1996 end-page: 120 article-title: Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale publication-title: Age Ageing – volume: 65 start-page: 1907 year: 2005 end-page: 1913 article-title: Visual dysfunction in Parkinson disease without dementia publication-title: Neurology – volume: 18 start-page: 668 year: 2003 end-page: 672 article-title: Sleepiness in Parkinson's disease: a controlled study publication-title: Mov Disord – volume: 25 start-page: 2649 year: 2010 end-page: 2653 article-title: Systematic review of levodopa dose equivalency reporting in Parkinson's disease publication-title: Mov Disord – volume: 121 start-page: 1819 year: 1998 end-page: 1840 article-title: Complex visual hallucinations. Clinical and neurobiological insights publication-title: Brain – volume: 289 start-page: 12 year: 2010 end-page: 17 article-title: Epidemiology of psychosis in Parkinson's disease publication-title: J Neurol Sci – article-title: Feeling of a presence in PD publication-title: J Neurol Neurosurg Psychiatry – volume: 22 start-page: 1689 year: 2007 end-page: 707 article-title: Clinical diagnostic criteria for dementia associated with Parkinson's disease publication-title: Mov Disord – ident: e_1_2_6_44_2 doi: 10.1002/mds.20308 – ident: e_1_2_6_7_2 doi: 10.1093/brain/121.10.1819 – ident: e_1_2_6_38_2 doi: 10.1016/j.jns.2009.08.014 – ident: e_1_2_6_6_2 doi: 10.1007/s00415-0060-0254-4 – ident: e_1_2_6_39_2 doi: 10.1002/mds.21956 – ident: e_1_2_6_43_2 doi: 10.1017/S0140525X05000130 – ident: e_1_2_6_46_2 doi: 10.1093/brain/awp223 – ident: e_1_2_6_8_2 doi: 10.1002/mds.20582 – ident: e_1_2_6_26_2 doi: 10.1001/archneur.61.1.97 – ident: e_1_2_6_49_2 doi: 10.1002/mds.22829 – ident: e_1_2_6_20_2 doi: 10.1111/j.1600-0404.2007.00818.x – ident: e_1_2_6_33_2 doi: 10.1177/089198879901200403 – volume: 33 start-page: 144 year: 1996 ident: e_1_2_6_34_2 article-title: Ocular motility in Parkinson's disease publication-title: J Pediatr Ophthalmol Strabismus doi: 10.3928/0191-3913-19960501-04 – ident: e_1_2_6_40_2 doi: 10.1016/S0140-6736(96)90869-7 – ident: e_1_2_6_2_2 doi: 10.1212/01.WNL.0000103444.45882.D8 – ident: e_1_2_6_29_2 doi: 10.1002/gps.1965 – ident: e_1_2_6_17_2 doi: 10.1136/jnnp.55.3.181 – ident: e_1_2_6_31_2 doi: 10.1016/j.visres.2004.11.006 – volume: 23 issue: 2 year: 2002 ident: e_1_2_6_41_2 article-title: Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8‐year follow‐up publication-title: Neurolog Sci – ident: e_1_2_6_32_2 doi: 10.1016/0022-3956(75)90026-6 – ident: e_1_2_6_48_2 doi: 10.1001/archneurol.2009.221 – ident: e_1_2_6_24_2 doi: 10.1176/jnp.12.2.233 – ident: e_1_2_6_3_2 doi: 10.1002/mds.20844 – year: 2008 ident: e_1_2_6_15_2 article-title: Motion integration deficits are independent of magnocelluar impairment in Parkinson's disease publication-title: Neuropsychologia – ident: e_1_2_6_47_2 doi: 10.1212/01.WNL.0000141853.27081.BD – ident: e_1_2_6_22_2 doi: 10.1007/PL00007730 – ident: e_1_2_6_35_2 doi: 10.1192/bjp.169.4.459 – ident: e_1_2_6_45_2 doi: 10.1016/j.parkreldis.2010.01.003 – ident: e_1_2_6_14_2 doi: 10.1212/WNL.42.4.887 – volume: 21 start-page: 289 year: 1998 ident: e_1_2_6_16_2 article-title: Poor visual discrimination and visual hallucinations in Parkinson's disease publication-title: Clin Neuropharmacol – ident: e_1_2_6_37_2 doi: 10.1001/archneur.1996.00550120077019 – ident: e_1_2_6_11_2 doi: 10.1177/0891988705284739 – ident: e_1_2_6_28_2 doi: 10.1002/mds.23429 – ident: e_1_2_6_27_2 doi: 10.1002/mds.10429 – ident: e_1_2_6_12_2 doi: 10.1093/brain/110.6.1675 – ident: e_1_2_6_10_2 article-title: Feeling of a presence in PD publication-title: J Neurol Neurosurg Psychiatry – ident: e_1_2_6_13_2 doi: 10.1212/01.wnl.0000191565.11065.11 – ident: e_1_2_6_30_2 doi: 10.1001/archopht.119.7.1050 – ident: e_1_2_6_18_2 doi: 10.1002/mds.21507 – ident: e_1_2_6_36_2 doi: 10.1136/jnnp.63.4.434 – ident: e_1_2_6_5_2 doi: 10.1016/S0165-1781(00)00227-4 – ident: e_1_2_6_9_2 doi: 10.1002/mds.23411 – volume: 58 start-page: A509 year: 2002 ident: e_1_2_6_25_2 article-title: Validation of a questionnaire for the diagnosis of REM sleep behavior disorder publication-title: Neurology – ident: e_1_2_6_4_2 doi: 10.1093/brain/123.4.733 – ident: e_1_2_6_19_2 doi: 10.1093/ageing/25.2.113 – ident: e_1_2_6_21_2 doi: 10.1016/S1353-8020(99)00062-0 – ident: e_1_2_6_23_2 doi: 10.1136/jnnp.51.11.1401 – ident: e_1_2_6_42_2 doi: 10.1212/WNL.0b013e3181fd6158 |
SSID | ssj0011516 |
Score | 2.4429717 |
Snippet | Visual symptoms are common in PD and PD dementia and include difficulty reading, double vision, illusions, feelings of presence and passage, and complex visual... |
SourceID | proquest pubmed pascalfrancis crossref wiley istex |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 2387 |
SubjectTerms | Aged Biological and medical sciences Cognition Disorders - diagnosis Cognition Disorders - physiopathology complex visual hallucinations contrast sensitivity Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Dementia - diagnosis Dementia - physiopathology Female Hallucinations - diagnosis Hallucinations - physiopathology Humans Male Medical sciences Neurology Neuropsychological Tests Parkinson Disease - diagnosis Parkinson Disease - physiopathology Parkinson's disease Parkinson's disease dementia Psychiatric Status Rating Scales Severity of Illness Index Vision Disorders - diagnosis Vision Disorders - physiopathology visual acuity |
Title | Visual symptoms in Parkinson's disease and Parkinson's disease dementia |
URI | https://api.istex.fr/ark:/67375/WNG-FQZCT7R6-L/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fmds.23891 https://www.ncbi.nlm.nih.gov/pubmed/21953737 https://www.proquest.com/docview/905963208 |
Volume | 26 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3rS9xAEB9EofRLa2sfUSuhiO2XnMlmX6GfivaU4gm12kopLPsKHHo5MXeg_eu7u3nIlSuUQj6EMEsyMzu7k52Z3wDsGoO1hyZKeKZVgiUqEkmRTpjPpiptqXLji5NHp_T4An--JJcr8KGrhWnwIfoDN28ZYb32Bi5Vvf8AGjox9QD5KJtbf7Ocetz8w7MeOso5OqHtqTMiEiqEO1ShFO33Ixf2ojUv1jufGylrJ56y6WuxzPFc9GPDRjR8Cj87Fpr8k6vBfKYG-tcf6I7_yeM6PGkd1PhjM6OewYqtnsOjURuC34Cjb-N67gjq-8nNbDqp43EV-9LpUEX2ro7biE8sK7P0uQnnkWP5Ai6Gn84PjpO2G0OiMeFZwjRJFSndDxinrLSSKCJTojElSCosDUXMUJIzm0tGs7I0zveROJPOP2GpUSR_CavVtLKvIUZcY46R4thdxGIlkcpKyS2XhSpYHsH7Ti9Ct1DlvmPGtWhAlpFwghFBMBG87UlvGnyOZUR7Qbk9hePeJ7QxIr6fHonhlx8H5-yMipMIdha03w9ABFGEeRFB3E0H4ezQB1dkZafzWhS-j1GOUh7Bq2aaPAz2oUr3NsdWUPbfP1SMDr-Gm81_J92Cx-GcO9RHbsPq7HZu3zhHaaZ2gkX8Bop4DSQ |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ri9NAEB_OO1C_-H7ExxlE1C_pJZt9Bfwip72qbcGzp4cgy74CRZsepgX1r3d38zgqFUTIhxBmSWZmJ5nM4zcAT4zB2kMTJTzTKsESFYmkSCfMV1OVtlS58c3JkykdneC3p-R0B150vTANPkQfcPOWEd7X3sB9QPrgHDV0YeoB8mm2C7AX8nPeJTruwaOcqxMGnzozIqFHuMMVStFBv3Tja7TnBfvDV0fK2gmobCZbbHM9Nz3Z8CkaXoUvHRNNBcrXwXqlBvrXH_iO_8vlNbjS-qjxy2ZTXYcdW92Ai5M2C38Tjj7O67UjqH8uzlbLRR3Pq9h3T4dGsmd13CZ9YlmZrddNCEnO5S04Gb6eHY6SdiBDojHhWcI0SRUp3T8Yp6y0kigiU6IxJUgqLA1FzFCSM5tLRrOyNM79kTiTzkVhqVEkvw271bKydyFGXGOOkeLYHcRiJZHKSsktl4UqWB7B804xQrdo5X5oxjfR4Cwj4QQjgmAieNyTnjUQHduIngbt9hSOe1_Txoj4ND0Sw_efD2fsmIpxBPsb6u8XIIIowryIIO72g3Cm6PMrsrLLdS0KP8ooRymP4E6zT84X-2ylu5tjK2j77w8qJq8-hJN7_076CC6NZpOxGL-ZvrsPl0PYO7RLPoDd1fe1fej8ppXaD-bxG1edEUI |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ra9RAEB9qC8Uv9a3xUYOI-iXXZLOv4CdpvVbtHVpbLSIs-woc9XKHuQP1r3d38ygnJ4iQDyHMcjczO9lfdnZ-A_DUGKw9NVHCM60SLFGRSIp0wvxpqtKWKje-OHk0pkdn-O05Od-Al10tTMMP0W-4-cgI72sf4HNT7l2Shk5NPUA-y3YFtjB1y6RHRCc9d5RDOqHvqYsiEkqEO1qhFO31Q1cWoy1v1x_-cKSsnX3KprHFOuS5CmTDSjS8Bl87HZoDKBeD5UIN9K8_6B3_U8nrsNMi1PhVM6VuwIatbsL2qM3B34LDT5N66QTqn9P5Yjat40kV-9rpUEb2vI7blE8sK7P2uQkbkhN5G86Gr0_3j5K2HUOiMeFZwjRJFSndFxinrLSSKCJTojElSCosDUXMUJIzm0tGs7I0DvxInEkHUFhqFMnvwGY1q-w9iBHXmGOkOHYXsVhJpLJScstloQqWR_Ci84vQLVe5b5nxTTQsy0g4w4hgmAie9KLzhqBjndCz4NxewmnvT7QxIj6PD8Xww5f9U3ZCxXEEuyve7wcggijCvIgg7qaDcIHosyuysrNlLQrfyChHKY_gbjNNLgf7XKX7NadWcPbf_6gYHXwMN_f_XfQxbL8_GIrjN-N3D-Bq2PMOtZIPYXPxfWkfOdC0ULshOH4DGZwP8Q |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Visual+symptoms+in+Parkinson%27s+disease+and+Parkinson%27s+disease+dementia&rft.jtitle=Movement+disorders&rft.au=Archibald%2C+Neil+K.&rft.au=Clarke%2C+Mike+P.&rft.au=Mosimann%2C+Urs+P.&rft.au=Burn%2C+David+J.&rft.date=2011-11-01&rft.pub=Wiley+Subscription+Services%2C+Inc.%2C+A+Wiley+Company&rft.issn=0885-3185&rft.eissn=1531-8257&rft.volume=26&rft.issue=13&rft.spage=2387&rft.epage=2395&rft_id=info:doi/10.1002%2Fmds.23891&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_WNG_FQZCT7R6_L |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0885-3185&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0885-3185&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0885-3185&client=summon |